newsfilter
← Latest News
GlobeNewswire·

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results

ALGS
  • Aligos Therapeutics reported third-quarter 2025 financial results & business progress on November 6, 2025.
  • The Phase 2 B-SUPREME study of pevifoscorvir sodium for chronic HBV enrolled its first patient in August 2025 with subjects dosed in the U.S., China, Hong Kong, & Canada.
  • Interim data for the pevifoscorvir sodium Phase 2 study is projected for the first & second halves of 2026, with top-line data anticipated in 2027.
  • Aligos will present 96-week Phase 1 pevifoscorvir sodium data at AASLD's The Liver Meeting in November 2025, including four abstracts & one oral presentation.
  • Preclinical data for ALG-055009 combined with incretin receptor agonists showed profound synergistic weight loss & enhanced antihyperlipidemic effects in obese mouse models.
  • Discussions regarding potential out-licensing & funding options for the ALG-055009 obesity & MASH pipeline are ongoing.
  • Cash, cash equivalents, & investments totaled $99.1 million as of September 30, 2025, providing sufficient funding through the third quarter of 2026.
  • Net loss for the three months ended September 30, 2025, was $31.5 million ($3.04 per share), compared to $19.3 million ($3.07 per share) in the prior-year period.
  • Research & development expenses rose to $23.9 million in the quarter, driven by increased third-party costs for the pevifoscorvir sodium Phase 2a trial.
  • General & administrative expenses increased to $5.2 million due to higher legal & related costs.
  • A loss of $4.2 million was recorded for the change in fair value of 2023 common warrants, compared to a $0.1 million loss in the prior year.